Treatment of skin cancers in epidermolysis bullosa

Dermatologic Clinics

Volumn 28, Issue 2, 2010, Pages 283-287

  Venugopal, Supriya S ^a   Murrell, Dédée F ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biopsy; Diagnosis; Epidermolysis bullosa

Indexed keywords

AMINOLEVULINIC ACID; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CETUXIMAB; DOXYCYCLINE FOSFATEX; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETRETIN; ISOTRETINOIN; MINOCYCLINE;

ACNE; ALLERGIC REACTION; BOWEN DISEASE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOSURGERY; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DISTANT METASTASIS; DRUG MECHANISM; DRUG TOLERABILITY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; HEAD CANCER; HUMAN; INTERMETHOD COMPARISON; LIMB AMPUTATION; LOW DRUG DOSE; LUNG CANCER; MALAISE; NAUSEA; NECK CANCER; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SKIN BIOPSY; SKIN CANCER; SKIN EXAMINATION; SQUAMOUS CELL CARCINOMA; VOMITING;

BIOPSY; CARCINOMA, SQUAMOUS CELL; EPIDERMOLYSIS BULLOSA; HUMANS; SKIN NEOPLASMS;

EID: 77952499409     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.01.009     Document Type: Review

References (36)

1. Fine J.D., Johnson L.B., Suchindran C., et al. Premature death and inherited epidermolysis bullosa. Epidermolysis bullosa: clinical, epidemiologic, and laboratory advances, and the findings of the National Epidermolysis Bullosa Registry 1999, vol. 1:206-224. Johns Hopkins University Press, Baltimore (MD). 1st edition. J.D. Fine, E.A. Bauer, J. McGuire (Eds.).
2. Fine J.D., Johnson L.B., Weiner M., et al. Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006. J Am Acad Dermatol 2009, 60(2):203-211.
3. Rodeck U., Uitto J. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis. J Invest Dermatol 2007, 127(10):2295-2296. [comment].
4. Rodeck U., Fertala A., Uitto J. Anchorless keratinocyte survival: an emerging pathogenic mechanism for squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Exp Dermatol 2007, 16(6):465-467. [review].
5. Pourreyron C., Cox G., Mao X., et al. Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression. J Invest Dermatol 2007, 127(10):2438-2444. [see comment].
6. McGrath JA, Schofield OM, Mayou BJ, et al. Epidermolysis bullosa complicated by squamous cell carcinoma: report of 10 cases. J Cutan Pathol 1992, 19(2):116-123.
7. Mallipeddi R., Wessagowit V., South A.P., et al. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2004, 122(5):1302-1309.
8. Arbiser J.L., Fine J.D., Murrell D., et al. Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Mol Med 1998, 4(3):191-195.
9. Arbiser J.L., Fan C.Y., Su X., et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 2004, 123(4):788-790.
10. Garcia-Morales I., Perez-Gil A., Camacho F.M. Actas Dermosifiliogr 2006, 97(8):529-532. [in Spanish].
11. Copcu E., Sivrioglu N., Baytekin C., et al. Very acute and aggressive form of Marjolin's ulcer caused by single blunt trauma to the burned area. J Burn Care Rehabil 2005, 26(5):459-460.
12. Wong A., Johns M.M., Teknos T.N. Marjolin's ulcer arising in a previously grafted burn of the scalp. Otolaryngol Head Neck Surg 2003, 128(6):915-916.
13. Smith J., Mello L.F., Nogueira Neto N.C., et al. Malignancy in chronic ulcers and scars of the leg (Marjolin's ulcer): a study of 21 patients. Skeletal Radiol 2001, 30(6):331-337.
14. Dupree M.T., Boyer J.D., Cobb M.W. Marjolin's ulcer arising in a burn scar. Cutis 1998, 62(1):49-51.
15. Fishman J.R., Parker M.G. Malignancy and chronic wounds: Marjolin's ulcer. J Burn Care Rehabil 1991, 12(3):218-223.
16. Kawasaki H., Sawamura D., Iwao F., et al. Squamous cell carcinoma developing in a 12-year-old boy with nonHallopeau-Siemens recessive dystrophic epidermolysis bullosa. Br J Dermatol 2003, 148(5):1047-1050. [review].
17. Murrell D. Photographic monitoring for squamous cell carcinoma in RDEB. Proceedings of the International EB Professionals Congress 2003, Institute for Child Health, London.
18. Fine J.D., Johnson L.B., Weiner M., et al. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin. J Am Acad Dermatol 2004, 50(4):563-571.
19. Smit J.V., de Sevaux R.G., Blokx W.A., et al. Acitretin treatment in (pre)malignant skin disorders of renal transplant recipients: histologic and immunohistochemical effects. J Am Acad Dermatol 2004, 50(2):189-196.
20. Lebwohl M., Tannis C., Carrasco D. Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat 2003, 14(Suppl 2):3-6. [review].
21. George R., Weightman W., Russ G.R., et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002, 43(4):269-273.
22. Fritsch A., Loeckermann S., Kern J.S., et al. Ahypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy. J Clin Invest 2008, 118:1669-1679.
23. Souza C.S., Felicio L.B., Bentley M.V., et al. Topical photodynamic therapy for Bowen's disease of the digit in epidermolysis bullosa. Br J Dermatol 2005, 153(3):672-674. [review].
24. Saxena A, Lee JB, Humphreys TR Mohs micrographic surgery for squamous cell carcinoma associated with epidermolysis bullosa. Dermatol Surg 2006, 32(1):128-134.
25. Rokunohe A., Nakano H., Aizu T., et al. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa. J Dermatol 2008, 35(6):336-340.
26. Perez-Naranjo L., Herrera-Saval A., Garcia-Bravo B., et al. Sentinel lymph node biopsy in recessive dystrophic epidermolysis bullosa and squamous cell carcinoma. Arch Dermatol 2005, 141(1):110-111.
27. Fine J-.D. Possible role of sentinel node biopsy in the management of squamous cell carcinomas in inherited epidermolysis bullosa. Arch Dermatol 2004, 140:1012-1013.
28. Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin 2007, 28(9):1476-1493. [review].
29. Suen J.K., Bressler L., Shord S.S., et al. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007, 18(7):827-829.
30. Reuter C.W., Morgan M.A., Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 2007, 96(3):408-416. [review].
31. Le Tourneau C., Siu L.L. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 2008, 20(3):256-263. [review].
32. Le Tourneau C., Chen E.X. Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am 2008, 22(6):1209-1220. [review], ix.
33. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25(16):2171-2177.
34. Bouali S., Chretien A.S., Ramacci C., et al. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 2009, 21(3):731-735.
35. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578. [see comment].
36. Maubec E., Petrow P., Duvillard P., et al. Cetuximab as first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin: preliminary results of a phase II multicenter study. J Clin Oncol 2008, 26(Suppl). [abstract 9042].